CRVO
CRVO
NASDAQ · Biotechnology

Cervomed Inc

$2.67
+0.13 (+5.12%)
As of Sep 28, 10:29 PM ET ·
Financial Highlights (FY 2026)
Revenue
6.69M
Net Income
-45,002,431
Gross Margin
100.0%
Profit Margin
-673.1%
Rev Growth
—
D/E Ratio
—
Revenue & Net Income
Margin Trends
FY 2026 FY 2025 FY 2024 FY 2023
Gross Margin 100.0% 53.8% 53.8% 53.8%
Operating Margin -706.2% -0.9% -0.8% -0.8%
Profit Margin -673.1% -0.9% -1.0% -0.8%
Income Statement
FY 2026 FY 2025 FY 2024 FY 2023
Revenue 6.69M 8.74M 8.70M 9.10M
Gross Profit 6.69M 4.70M 4.68M 4.90M
Operating Income -47,218,462 -79,065 -65,603 -75,418
Net Income -45,002,431 -76,794 -87,592 -73,867
Gross Margin 100.0% 53.8% 53.8% 53.8%
Operating Margin -706.2% -0.9% -0.8% -0.8%
Profit Margin -673.1% -0.9% -1.0% -0.8%
Rev Growth — +8.7% -7.3% +10.0%
Balance Sheet
FY 2026 FY 2025 FY 2024 FY 2023
Total Debt 0 14.52M 12.48M 15.52M
Total Equity — 19.84M 19.63M 21.56M
D/E Ratio — 0.73 0.64 0.72
Cash Flow
FY 2026 FY 2025 FY 2024 FY 2023
EBITDA -47,220,563 -105,264 -93,337 -108,348
Free Cash Flow — -51,137 -57,721 -60,543